Acurx Pharmaceuticals Llc Stock Performance
| ACXP Stock | USD 2.06 0.08 3.74% |
The firm shows a Beta (market volatility) of 1.8, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acurx Pharmaceuticals will likely underperform. At this point, Acurx Pharmaceuticals LLC has a negative expected return of -1.17%. Please make sure to confirm Acurx Pharmaceuticals' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Acurx Pharmaceuticals LLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Acurx Pharmaceuticals LLC has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (3.74) | Five Day Return (1.44) | Year To Date Return (25.36) | Ten Year Return (98.69) | All Time Return (98.69) |
Last Split Factor 1:20 | Last Split Date 2025-08-05 |
1 | Acurx Pharmaceuticals GAAP EPS of -1.23 beats by 0.05 | 11/12/2025 |
2 | What is HC Wainwrights Forecast for ACXP FY2025 Earnings | 11/14/2025 |
3 | Disposition of 3125 shares by Sailer Carl of Acurx Pharmaceuticals at 4.0 subject to Rule 16b-3 | 11/28/2025 |
4 | Acurx Pharmaceuticals, Inc. Sees Significant Growth in Short Interest - Defense World | 12/24/2025 |
5 | Has Acurx Pharmaceuticals Outpaced Other Medical Stocks This Year | 01/06/2026 |
6 | USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors | 02/02/2026 |
Acurx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 474.00 in Acurx Pharmaceuticals LLC on November 13, 2025 and sell it today you would lose (268.00) from holding Acurx Pharmaceuticals LLC or give up 56.54% of portfolio value over 90 days. Acurx Pharmaceuticals LLC is currently does not generate positive expected returns and assumes 6.9525% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Acurx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acurx Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Acurx Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.06 | 90 days | 2.06 | more than 93.0 |
Based on a normal probability distribution, the odds of Acurx Pharmaceuticals to move above the current price in 90 days from now is more than 93.0 (This Acurx Pharmaceuticals LLC probability density function shows the probability of Acurx Stock to fall within a particular range of prices over 90 days) .
Acurx Pharmaceuticals Price Density |
| Price |
Predictive Modules for Acurx Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Acurx Pharmaceuticals LLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acurx Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Acurx Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Acurx Pharmaceuticals is not an exception. The market had few large corrections towards the Acurx Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Acurx Pharmaceuticals LLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Acurx Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.32 | |
β | Beta against Dow Jones | 1.80 | |
σ | Overall volatility | 0.89 | |
Ir | Information ratio | -0.18 |
Acurx Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Acurx Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Acurx Pharmaceuticals LLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Acurx Pharmaceuticals generated a negative expected return over the last 90 days | |
| Acurx Pharmaceuticals has high historical volatility and very poor performance | |
| Acurx Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (14.1 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acurx Pharmaceuticals LLC currently holds about 9.09 M in cash with (10.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8. | |
| Acurx Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors |
Acurx Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Acurx Stock often depends not only on the future outlook of the current and potential Acurx Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acurx Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 851.5 K | |
| Cash And Short Term Investments | 3.7 M |
Acurx Pharmaceuticals Fundamentals Growth
Acurx Stock prices reflect investors' perceptions of the future prospects and financial health of Acurx Pharmaceuticals, and Acurx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acurx Stock performance.
| Return On Equity | -2.91 | ||||
| Return On Asset | -0.96 | ||||
| Current Valuation | (456.83 K) | ||||
| Shares Outstanding | 2.55 M | ||||
| Price To Book | 1.50 X | ||||
| EBITDA | (14.1 M) | ||||
| Net Income | (14.1 M) | ||||
| Cash And Equivalents | 9.09 M | ||||
| Cash Per Share | 0.80 X | ||||
| Total Debt | 3.24 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 19.43 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (10.38 M) | ||||
| Earnings Per Share | (8.18) X | ||||
| Market Capitalization | 5.45 M | ||||
| Total Asset | 3.86 M | ||||
| Retained Earnings | (67.32 M) | ||||
| Working Capital | 615.12 K | ||||
About Acurx Pharmaceuticals Performance
Assessing Acurx Pharmaceuticals' fundamental ratios provides investors with valuable insights into Acurx Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acurx Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.20) | (4.41) | |
| Return On Capital Employed | (26.37) | (25.05) | |
| Return On Assets | (4.20) | (4.41) | |
| Return On Equity | (26.37) | (25.05) |
Things to note about Acurx Pharmaceuticals LLC performance evaluation
Checking the ongoing alerts about Acurx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acurx Pharmaceuticals LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acurx Pharmaceuticals generated a negative expected return over the last 90 days | |
| Acurx Pharmaceuticals has high historical volatility and very poor performance | |
| Acurx Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (14.1 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acurx Pharmaceuticals LLC currently holds about 9.09 M in cash with (10.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8. | |
| Acurx Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors |
- Analyzing Acurx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acurx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Acurx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acurx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acurx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acurx Pharmaceuticals' stock. These opinions can provide insight into Acurx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.